Google Expands Its Transparency Report

In its latest “Transparency Report,” released Monday, Internet search engine No. 1, Google (GOOGL), said that the number of requests from courts and government agencies around the world to remove information from its sites slightly decreased during its most recent reporting period. Google said in a blog post that between June and December 2013, it fielded 3,105 requests to remove 14,637 pieces of content, with its Blogger, Search and YouTube

Palo Alto Networks Price Target Hiked On Portfolio

Palo Alto Networks (PANW) got price target hikes Monday as analysts say the network security vendor will benefit from enterprises needing comprehensive portfolios to beef up their cyberdefenses amid a rising number of high-profile breaches. Palo Alto Networks stock touched an all-time high for the third straight day, though the IBD Leaderboard stock is well extended from its 85.88 breakout from a flat base. “In our view, Palo Alto has one of the

Oracle Hikes Online Marketing Cloud With Datalogix

Oracle (ORCL) is making another thrust to compete better with Salesforce.com and others in the data marketing cloud field. The enterprise software giant said on Monday that it’s agreed to acquire Datalogix, which makes software for connecting consumer spending to digital marketing in order to help companies measure and increase the effectiveness of their ad programs. Terms weren’t disclosed. But in a research report Monday, Brian Wieser, an

MacroGenics Partners With J&J; Stock Jumps

Biotech MacroGenics (MGNX) cut a licensing deal worth as much as $700 million with Johnson & Johnson’s drug-development arm Monday, sending its stock up 11% to a 10-month high above 38 on the stock market today. Johnson & Johnson’s (JNJ) unit Janssen Biotech agreed to pay $50 million upfront for rights to MacroGenics’ MGD011, an antibody that targets two biomarkers associated with malignancies of the B-cell, a type of white blood cell. Janssen

Express Scripts Picks AbbVie HCV Drugs Over Gilead

Pharmacy benefit manager Express Scripts (ESRX) announced Monday that it’s putting AbbVie’s newly approved hepatitis C treatment on its preferred formulary list and knocking off Gilead Sciences’ rivals. Gilead plunged 13% in morning trading in the stock market today, and AbbVie (ABBV) was down nearly 1%. Late Friday, the FDA approved Viekira Pak, a combination of three novel drugs along with an older product called ritonavir, as the second